Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CAR-NK Cell
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : GI CELL
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Announcement of Research License and Option Agreement with GI CELL
Details : CAR-NK cells represent antigen receptors against tumor-associated antigens (TAAs), thereby redirecting the effector NK cells and supporting tumor-related immunosurveillance.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 13, 2022
Lead Product(s) : CAR-NK Cell
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : GI CELL
Deal Size : Undisclosed
Deal Type : Licensing Agreement